Yahoo Web Search

Search results

1. • 

     Summit Therapeutics' Lung Cancer Therapy Ivonescimab Shows Improved Progression-Free Survival Versus...

     Benzinga via Yahoo Finance· 3 days ago

     HARMONi-2 evaluated monotherapy ivonescimab against monotherapy pembrolizumab in patients with ...

2. • 

     Cullinan Therapeutics announces success for zipalertinib as combo therapy

     Clinical Trials Arena via Yahoo Finance· 6 hours ago

     (amivantamab) is indicated for use in combination with carboplatin-pemetrexed chemotherapy for the...

3. • 

     Summit Therapeutics sees stock soar 272% after lung cancer clinical trial - Silicon Valley Business...

     The Business Journals· 4 days ago

     Summit (Nasdaq: SMMT) — led by the team that scored success with blood cancer drug developer...

4. • Innovent Announces Data from Pivotal Phase 2 TRUST-I Study of Taletrectinib（ROS1 Inhibitor) are...

     Tehachapi News· 2 days ago

     Data were reported from 173 patients with advanced ROS1-positive non-small cell lung cancer (NSCLC) who were treated with taletrectinib ...

5. • 

     Gilead's (GILD) Urothelial Cancer Study Did Not Meet Its Primary Goal

     Zacks via Yahoo Finance· 3 days ago

     Gilead Sciences, Inc.'s (GILD) confirmatory TROPiCS-04 study on Trodelvy in locally advanced or...

6. • First results from late-breaking Phase 3 PALOMA-3 study show five-fold reduction in infusion-related...

     Forrest City Times-Herald· 3 days ago

     Johnson & Johnson announced today first data from the Phase 3 PALOMA-3 study evaluating subcutaneous (SC) amivantamab combined with lazertinib in patients with locally < ...

7. • Improved Outcomes With Subcutaneous Amivantamab in NSCLC

     Medscape· 1 day ago

     Subcutaneous amivantamab plus lazertinib may offer a survival benefit over intravenous administration, alongside dramatically reduced administration times, a new study suggests.

8. • 

     Why Is AstraZeneca Stock Trading Lower On Tuesday?

     Benzinga via AOL· 6 days ago

     (NASDAQ:AZN) said the survival results did not reach statistical significance in the overall trial population in the TROPION-Lung01 phase 3 trial....

9. • Small Business - The Roanoke-Chowan News-Herald | The Roanoke-Chowan News-Herald

     Roanoke-Chowan News-Herald· 1 day ago

     Sugemalimab is expected to become the first anti-PD-L1 monoclonal antibody (mAb) in the world approved in Europe for both first-line squamous and non-squamous NSCLC, regardless of PD-L1 expression ...

10. • ...Moderna, Merck Reveal Three Year Data For Individualized Cancer Therapy In High-Risk Melanoma...

      Benzinga· 2 hours ago

      Monday, Moderna Inc MRNA and Merck & Co Inc MRK announced the first presentation of results from a planned analysis from the Phase 2b KEYNOTE-942/mRNA-4157-P201 study. The study is evaluating ...